Ford Motor Co. (F):
Consumer Discretionary – Automobiles | Reports July 26th, BMO.
The Estimize consensus calls for EPS of $.45, one cent higher than the Wall Street consensus and a decrease of 15% YoY. Currently, the Estimize community is looking for sales of $38.09B, which is slightly higher than the Street’s, $37.9B.
Last quarter the American car company posted a beat for both their revenue and EPS, but does this mean a turnaround for a company sitting near its 52-week low? When the company releases investors will be listening closely to the new CEO on how he will improve their bottom-line as well as staying ahead of the technology curve. Last month Ford saw a 9.8% increase in their F-Series trucks, and this could continue to be a bright spot with oil prices staying relatively low. Finally, investors will be interested in how Fordwill market their vehicles to consumers overseas, specifically China.
Gilead Sciences Inc. (GILD):
Healthcare – Biotechnology | Reports July 26th, AMC.
The Estimize consensus calls for EPS of $2.21, three cents higher than the Wall Street consensus, however a decrease of 29% YoY. Currently, the Estimize community is looking at revenue of $6.45B, which is slightly more optimistic than the Street ($6.36B). Check out the Estimize website to see our prediction for Arrival Sales.
Gilead has been underperforming in comparison to the broader market and the reason is not a mystery. Gilead’s revenue from their Hepatitis C drug has been falling, in 2016 they were down 22.5% YoY and accounted for 50% of their total product sales. However, the positive is that Gilead recently received FDA approval for their chronic Hepatitis C drug, Vosevi. This new drug will help them gain a larger portion of the Hep C market, with patients who did not respond to other drugs.
The Coca-Cola Company (KO):
Consumer Staples – Beverages | Reports July 26th, BMO.
The Estimize consensus calls for EPS of $.58, one cent higher than the Wall Street consensus and a decrease of 5% YoY. Currently, the Estimize community is looking for sales of $9.8B which is roughly in line with the street.
No Comments